(MENAFN- PR Newswire) EMERYVILLE, Calif., May 8, 2023 /PRNewswire/ -- dynavax technologies corporation (Nasdaq: dvax ), a commercial-stage biopharmaceutical company developing and
commercializing innovative vaccines, today announced that the Company will participate in a fireside chat at the JMP Securities Life Sciences Conference on Monday, May 15, at 1:00 p.m. E.T.

The presentation will be webcast and may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at .

About Dynavax

Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. The Company has two commercial products, HEPLISAV-B® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the U.S., the European Union and Great Britain for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older, and CpG 1018® adjuvant, currently used in multiple adjuvanted COVID-19 vaccines. Dynavax is advancing CpG 1018 adjuvant as a premier vaccine adjuvant with adjuvanted vaccine clinical programs for shingles and Tdap, and through global collaborations, currently focused on adjuvanted vaccines for COVID-19, plague, seasonal influenza and universal influenza. For more information about our marketed products and development pipeline, visit and follow Dynavax on linkedin
and twitter .

For Investors/Media:
Paul Cox
[email protected]
917-754-0207

Nicole Arndt
[email protected]
510-665-7264

SOURCE Dynavax Technologies

MENAFN08052023003732001241ID1106203485